MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

LY2811376

CAS No. : 1194044-20-6

MCE 国际站：LY2811376

产品活性：LY2811376 是一种可口服的，非肽段的 β-secretase (BACE1) 抑制剂，IC₅₀ 值为 239 nM-249 nM，能够降低 Aβ 蛋白的分泌，EC₅₀ 值为 300 nM。

研究领域：Neuronal Signaling

作用靶点：Beta-secretase

In Vitro: In an APP-overexpressing human embryonic kidney cell line, LY2811376 treatment yields a concentration-dependent decrease in Aβ secretion with a half-maximal effective concentration (EC₅₀) of appr 300 nM. LY2811376 treatment of primary neuronal cultures of PDAPP transgenic mouse produces a concentration-dependent decrease in Aβ secretion with an EC₅₀ of appr 100 nM. LY2811376 has good ADME properties (BACE1 IC₅₀=240 nM, cellular potency IC₅₀=300 nM) and selectivity (BACE2 and cathepsin D selectivity: appr 10- and 65-fold, respectively). LY2811376 reduces the Aβ40 levels in cortex and plasma without change of health and weight in a dose-dependent manner.

In Vivo: LY2811376 (10, 30, and 100 mg/kg, p.o.) results in dose-dependent, significant reductions in Aβ as well as sAPPβ and C99, the proximal cleavage products of APP proteolysis by BACE1. LY2811376 produces dose-dependent decreases in all APP-related PD markers of BACE1 inhibition in PDAPP mice. Low (30 mg) and high (90 mg) doses of LY2811376 investigated in the CSF sampling study are based on PK and plasma Aβ^1-40 PD observed in the SAD study. LY2811376 (30 mg/kg, p.o.) can lead to a 60% decrease in the soluble Aβs in mouse cortex. LY2811376 (100 mg/kg, p.o.) decreases the spine density and formation in mice. LY2811376 (100 mg/kg every 12 hours over 16 days) causes a reduction in the frequency of sEPSC and mEPSC, whereas the effects of LY2811376 on the amplitude of sEPSC fails to reach significance.

相关产品：Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Neuronal Signaling Compound Library  |  Clinical Compound Library  |  Orally Active Compound Library  |  Anti-Alzheimer's Disease Compound Library  |  Neurodegenerative Disease-related Compound Library  |  Heterocyclic Compound Library  |  Membrane Protein-targeted Compound Library  |  LY2886721  |  Eslicarbazepine acetate  |  AChE/BChE/BACE-1-IN-2  |  BACE1-IN-6  |  Memoquin  |  Kushenol C  |  AChE/BChE/BACE-1-IN-1  |  BACE1-IN-5  |  NB-360  |  BACE1-IN-11  |  AChE/BACE1/GSK3β-IN-1  |  AChE/BChE-IN-12  |  BACE-1 inhibitor 2  |  Epiberberine  |  β-Secretase Inhibitor IV  |  Tenuifolin  |  AZD3839 free base  |  Umibecestat  |  BACE1-IN-12  |  BACE-1 inhibitor 1  |  Sophoflavescenol  |  BACE1-IN-1  |  BACE2-IN-1  |  hAChE/hBACE-1-IN-2  |  Aloenin  |  BACE-IN-1  |  Scoulerine  |  JNJ-67569762

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。